{
  "as_of": "2026-11-03",
  "track": "vaccines",
  "source_url": "https://drugnews.com.tw/en/asia-vaccines-leaders.html",
  "headers": [
    "rank",
    "asset",
    "inn",
    "originator",
    "country",
    "target",
    "mechanism",
    "highest_stage",
    "indications",
    "trial_ids",
    "overseas_rights_holder",
    "deal_date",
    "upfront",
    "total_value",
    "latest_event",
    "latest_event_date",
    "source_urls",
    "source_date"
  ],
  "rows": [
    [
      "1",
      "Tripecia",
      "Not disclosed",
      "CanSino Biologics",
      "China",
      "Diphtheria; tetanus; Bordetella pertussis",
      "Adsorbed diphtheria-tetanus-acellular pertussis combination vaccine",
      "Approved — China (2026-04)",
      "Prevention of diphtheria, tetanus and pertussis in children",
      "NCT05951725",
      "None reported",
      "—",
      "—",
      "—",
      "Company update confirms Tripecia as an approved three-component acellular pertussis vaccine",
      "2026-10-27",
      "https://www.cansinotech.com/detail-4899 | https://cansinotech.com/detail-5090 | https://clinicaltrials.gov/study/NCT05951725",
      "2026-10-27"
    ],
    [
      "2",
      "iPneucia",
      "Not disclosed",
      "CanSino Biologics",
      "China",
      "Streptococcus pneumoniae (13 serotypes)",
      "13-valent pneumococcal conjugate vaccine",
      "Approved — China (2025-06)",
      "Prevention of pneumococcal disease in infants and children",
      "NCT04841369",
      "None reported",
      "—",
      "—",
      "—",
      "Company announces NMPA marketing approval for its PCV13i vaccine",
      "2025-06-20",
      "https://cansinotech.com/detail-4545 | https://clinicaltrials.gov/study/NCT04841369",
      "2025-06-20"
    ],
    [
      "3",
      "Cecolin 9",
      "Not disclosed",
      "Xiamen Innovax Biotech / Xiamen University",
      "China",
      "HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58",
      "Recombinant nine-valent HPV virus-like-particle vaccine",
      "Approved — China (2025-05)",
      "Prevention of disease associated with nine HPV types",
      "Not disclosed",
      "None reported",
      "—",
      "—",
      "—",
      "Manufacturer confirms Cecolin 9 approval in Thailand during 2026; exact approval date not disclosed",
      "2026-10-21",
      "https://www.xiameninnovax.com/products/ | https://www.xiameninnovax.com/company/ | https://www.xiameninnovax.com/news/innovax-honored/ | https://www.xiameninnovax.com/news/from-china-to-the-world-ix-advancing-global-cervical-cancer-prevention-through-hpv-vaccine-innovation/",
      "2026-10-21"
    ],
    [
      "4",
      "Zhifei quadrivalent influenza vaccine",
      "Not disclosed",
      "Anhui Zhifei Biopharmaceutical / Chongqing Zhifei Biological Products",
      "China",
      "Influenza A and B viruses",
      "Inactivated quadrivalent split-virion influenza vaccine",
      "Approved — China (2025-03)",
      "Prevention of influenza in adults and children aged 3 years and older",
      "Not disclosed",
      "None reported",
      "—",
      "—",
      "—",
      "Company announces receipt of NMPA registration certificate for its quadrivalent influenza vaccine",
      "2025-03-21",
      "https://static.cninfo.com.cn/finalpage/2025-03-21/1222868326.PDF | https://www.zhifeishengwu.com/zh_CN/news/38/644.html",
      "2025-06-05"
    ],
    [
      "5",
      "REC610",
      "Not disclosed",
      "Jiangsu Recbio Technology",
      "China",
      "Varicella-zoster virus glycoprotein E",
      "Adjuvanted recombinant herpes zoster vaccine",
      "Registration — China (confirmed 2026-09; marketing-application stage)",
      "Prevention of herpes zoster in adults aged 40 years and older",
      "Not disclosed",
      "None reported",
      "—",
      "—",
      "—",
      "2026 interim report confirms marketing-application stage following phase 3 development",
      "2026-09-23",
      "https://www.recbio.cn/media/fuso3ewx/hkex-eps_20260923_12342475_0.pdf | https://www.recbio.cn/en/pipeline/pipeline/shingles/rec610/",
      "2026-09-23"
    ],
    [
      "6",
      "LZ901",
      "Not disclosed",
      "Beijing Luzhu Biotechnology",
      "China",
      "Varicella-zoster virus",
      "Recombinant herpes zoster vaccine",
      "Registration — China (2025-02; BLA accepted; approval not established)",
      "Prevention of herpes zoster",
      "NCT06088745",
      "None reported",
      "—",
      "—",
      "—",
      "Company reports publication of phase 3 results; its product page states BLA review remains ongoing",
      "2026-08-07",
      "https://www.luzhubiotech.com/techAndProduct/productInResearch | https://luzhubiotech.com/news/27 | https://www.luzhubiotech.com/ | https://clinicaltrials.gov/study/NCT06088745",
      "2026-08-07"
    ],
    [
      "7",
      "GBP410",
      "Not disclosed",
      "SK bioscience / Sanofi",
      "South Korea",
      "Streptococcus pneumoniae (21 serotypes)",
      "21-valent pneumococcal conjugate vaccine",
      "Phase 3 — global (confirmed 2026-09; underway)",
      "Prevention of pneumococcal disease in children",
      "Not disclosed",
      "Sanofi (co-development partner; commercialisation outside South Korea); SK bioscience (South Korea)",
      "2024-12-23",
      "Not disclosed (GBP410-specific allocation)",
      "Not disclosed",
      "Sanofi Q3 2026 pipeline reports phase 3 SP0202 and identifies SK bioscience as its partner; snapshot as of September 30",
      "2026-10-30",
      "https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2026/2026-q3-2026-results/2026_10_30_Sanofi_Q3_2026_Results.pdf | https://www.skbioscience.com/en/news/news_01_01?id=311&mode=2 | https://www.skbioscience.com/en/news/news_01_01?id=287&mode=2",
      "2026-10-30"
    ],
    [
      "8",
      "REC603",
      "Not disclosed",
      "Jiangsu Recbio Technology",
      "China",
      "HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58",
      "Recombinant nine-valent HPV virus-like-particle vaccine",
      "Phase 3 — China (confirmed 2026-09; ongoing follow-up)",
      "Prevention of HPV-related disease",
      "Not disclosed",
      "None reported",
      "—",
      "—",
      "—",
      "2026 interim report retains REC603 in phase 3 clinical development",
      "2026-09-23",
      "https://www.recbio.cn/media/fuso3ewx/hkex-eps_20260923_12342475_0.pdf | https://www.recbio.cn/en/pipeline/pipeline/cervical-cancers-genital-warts/rec603/",
      "2026-09-23"
    ]
  ],
  "row_sources": [
    [
      {
        "url": "https://www.cansinotech.com/detail-4899",
        "source_date": "2026-10-27"
      },
      {
        "url": "https://cansinotech.com/detail-5090",
        "source_date": "2026-10-27"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT05951725",
        "source_date": "2026-10-27"
      }
    ],
    [
      {
        "url": "https://cansinotech.com/detail-4545",
        "source_date": "2025-06-20"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT04841369",
        "source_date": "2025-06-20"
      }
    ],
    [
      {
        "url": "https://www.xiameninnovax.com/products/",
        "source_date": "2026-10-21"
      },
      {
        "url": "https://www.xiameninnovax.com/company/",
        "source_date": "2026-10-21"
      },
      {
        "url": "https://www.xiameninnovax.com/news/innovax-honored/",
        "source_date": "2026-10-21"
      },
      {
        "url": "https://www.xiameninnovax.com/news/from-china-to-the-world-ix-advancing-global-cervical-cancer-prevention-through-hpv-vaccine-innovation/",
        "source_date": "2026-10-21"
      }
    ],
    [
      {
        "url": "https://static.cninfo.com.cn/finalpage/2025-03-21/1222868326.PDF",
        "source_date": "2025-06-05"
      },
      {
        "url": "https://www.zhifeishengwu.com/zh_CN/news/38/644.html",
        "source_date": "2025-06-05"
      }
    ],
    [
      {
        "url": "https://www.recbio.cn/media/fuso3ewx/hkex-eps_20260923_12342475_0.pdf",
        "source_date": "2026-09-23"
      },
      {
        "url": "https://www.recbio.cn/en/pipeline/pipeline/shingles/rec610/",
        "source_date": "2026-09-23"
      }
    ],
    [
      {
        "url": "https://www.luzhubiotech.com/techAndProduct/productInResearch",
        "source_date": "2026-08-07"
      },
      {
        "url": "https://luzhubiotech.com/news/27",
        "source_date": "2026-08-07"
      },
      {
        "url": "https://www.luzhubiotech.com/",
        "source_date": "2026-08-07"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06088745",
        "source_date": "2026-08-07"
      }
    ],
    [
      {
        "url": "https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2026/2026-q3-2026-results/2026_10_30_Sanofi_Q3_2026_Results.pdf",
        "source_date": "2026-10-30"
      },
      {
        "url": "https://www.skbioscience.com/en/news/news_01_01?id=311&mode=2",
        "source_date": "2026-10-30"
      },
      {
        "url": "https://www.skbioscience.com/en/news/news_01_01?id=287&mode=2",
        "source_date": "2026-10-30"
      }
    ],
    [
      {
        "url": "https://www.recbio.cn/media/fuso3ewx/hkex-eps_20260923_12342475_0.pdf",
        "source_date": "2026-09-23"
      },
      {
        "url": "https://www.recbio.cn/en/pipeline/pipeline/cervical-cancers-genital-warts/rec603/",
        "source_date": "2026-09-23"
      }
    ]
  ],
  "records": [
    {
      "rank": "1",
      "asset": "Tripecia",
      "inn": "Not disclosed",
      "originator": "CanSino Biologics",
      "country": "China",
      "target": "Diphtheria; tetanus; Bordetella pertussis",
      "mechanism": "Adsorbed diphtheria-tetanus-acellular pertussis combination vaccine",
      "highest_stage": "Approved — China (2026-04)",
      "indications": "Prevention of diphtheria, tetanus and pertussis in children",
      "trial_ids": "NCT05951725",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company update confirms Tripecia as an approved three-component acellular pertussis vaccine",
      "latest_event_date": "2026-10-27",
      "source_urls": "https://www.cansinotech.com/detail-4899 | https://cansinotech.com/detail-5090 | https://clinicaltrials.gov/study/NCT05951725",
      "source_date": "2026-10-27"
    },
    {
      "rank": "2",
      "asset": "iPneucia",
      "inn": "Not disclosed",
      "originator": "CanSino Biologics",
      "country": "China",
      "target": "Streptococcus pneumoniae (13 serotypes)",
      "mechanism": "13-valent pneumococcal conjugate vaccine",
      "highest_stage": "Approved — China (2025-06)",
      "indications": "Prevention of pneumococcal disease in infants and children",
      "trial_ids": "NCT04841369",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company announces NMPA marketing approval for its PCV13i vaccine",
      "latest_event_date": "2025-06-20",
      "source_urls": "https://cansinotech.com/detail-4545 | https://clinicaltrials.gov/study/NCT04841369",
      "source_date": "2025-06-20"
    },
    {
      "rank": "3",
      "asset": "Cecolin 9",
      "inn": "Not disclosed",
      "originator": "Xiamen Innovax Biotech / Xiamen University",
      "country": "China",
      "target": "HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58",
      "mechanism": "Recombinant nine-valent HPV virus-like-particle vaccine",
      "highest_stage": "Approved — China (2025-05)",
      "indications": "Prevention of disease associated with nine HPV types",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Manufacturer confirms Cecolin 9 approval in Thailand during 2026; exact approval date not disclosed",
      "latest_event_date": "2026-10-21",
      "source_urls": "https://www.xiameninnovax.com/products/ | https://www.xiameninnovax.com/company/ | https://www.xiameninnovax.com/news/innovax-honored/ | https://www.xiameninnovax.com/news/from-china-to-the-world-ix-advancing-global-cervical-cancer-prevention-through-hpv-vaccine-innovation/",
      "source_date": "2026-10-21"
    },
    {
      "rank": "4",
      "asset": "Zhifei quadrivalent influenza vaccine",
      "inn": "Not disclosed",
      "originator": "Anhui Zhifei Biopharmaceutical / Chongqing Zhifei Biological Products",
      "country": "China",
      "target": "Influenza A and B viruses",
      "mechanism": "Inactivated quadrivalent split-virion influenza vaccine",
      "highest_stage": "Approved — China (2025-03)",
      "indications": "Prevention of influenza in adults and children aged 3 years and older",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company announces receipt of NMPA registration certificate for its quadrivalent influenza vaccine",
      "latest_event_date": "2025-03-21",
      "source_urls": "https://static.cninfo.com.cn/finalpage/2025-03-21/1222868326.PDF | https://www.zhifeishengwu.com/zh_CN/news/38/644.html",
      "source_date": "2025-06-05"
    },
    {
      "rank": "5",
      "asset": "REC610",
      "inn": "Not disclosed",
      "originator": "Jiangsu Recbio Technology",
      "country": "China",
      "target": "Varicella-zoster virus glycoprotein E",
      "mechanism": "Adjuvanted recombinant herpes zoster vaccine",
      "highest_stage": "Registration — China (confirmed 2026-09; marketing-application stage)",
      "indications": "Prevention of herpes zoster in adults aged 40 years and older",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "2026 interim report confirms marketing-application stage following phase 3 development",
      "latest_event_date": "2026-09-23",
      "source_urls": "https://www.recbio.cn/media/fuso3ewx/hkex-eps_20260923_12342475_0.pdf | https://www.recbio.cn/en/pipeline/pipeline/shingles/rec610/",
      "source_date": "2026-09-23"
    },
    {
      "rank": "6",
      "asset": "LZ901",
      "inn": "Not disclosed",
      "originator": "Beijing Luzhu Biotechnology",
      "country": "China",
      "target": "Varicella-zoster virus",
      "mechanism": "Recombinant herpes zoster vaccine",
      "highest_stage": "Registration — China (2025-02; BLA accepted; approval not established)",
      "indications": "Prevention of herpes zoster",
      "trial_ids": "NCT06088745",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Company reports publication of phase 3 results; its product page states BLA review remains ongoing",
      "latest_event_date": "2026-08-07",
      "source_urls": "https://www.luzhubiotech.com/techAndProduct/productInResearch | https://luzhubiotech.com/news/27 | https://www.luzhubiotech.com/ | https://clinicaltrials.gov/study/NCT06088745",
      "source_date": "2026-08-07"
    },
    {
      "rank": "7",
      "asset": "GBP410",
      "inn": "Not disclosed",
      "originator": "SK bioscience / Sanofi",
      "country": "South Korea",
      "target": "Streptococcus pneumoniae (21 serotypes)",
      "mechanism": "21-valent pneumococcal conjugate vaccine",
      "highest_stage": "Phase 3 — global (confirmed 2026-09; underway)",
      "indications": "Prevention of pneumococcal disease in children",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "Sanofi (co-development partner; commercialisation outside South Korea); SK bioscience (South Korea)",
      "deal_date": "2024-12-23",
      "upfront": "Not disclosed (GBP410-specific allocation)",
      "total_value": "Not disclosed",
      "latest_event": "Sanofi Q3 2026 pipeline reports phase 3 SP0202 and identifies SK bioscience as its partner; snapshot as of September 30",
      "latest_event_date": "2026-10-30",
      "source_urls": "https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2026/2026-q3-2026-results/2026_10_30_Sanofi_Q3_2026_Results.pdf | https://www.skbioscience.com/en/news/news_01_01?id=311&mode=2 | https://www.skbioscience.com/en/news/news_01_01?id=287&mode=2",
      "source_date": "2026-10-30"
    },
    {
      "rank": "8",
      "asset": "REC603",
      "inn": "Not disclosed",
      "originator": "Jiangsu Recbio Technology",
      "country": "China",
      "target": "HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58",
      "mechanism": "Recombinant nine-valent HPV virus-like-particle vaccine",
      "highest_stage": "Phase 3 — China (confirmed 2026-09; ongoing follow-up)",
      "indications": "Prevention of HPV-related disease",
      "trial_ids": "Not disclosed",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "2026 interim report retains REC603 in phase 3 clinical development",
      "latest_event_date": "2026-09-23",
      "source_urls": "https://www.recbio.cn/media/fuso3ewx/hkex-eps_20260923_12342475_0.pdf | https://www.recbio.cn/en/pipeline/pipeline/cervical-cancers-genital-warts/rec603/",
      "source_date": "2026-09-23"
    }
  ]
}